 Thanks to everyone. Thanks to the Brain Foundation and all the sponsors. If you could speak please. Yeah, sorry. I'm very honoured and grateful to be here tonight and obviously it's really meaningful for us in our department, but it's also hopefully going to translate into something that's really meaningful for the patients, the results of our study and the implications of that. So I actually work at the Martyr Advanced Epilepsy Unit which is a large stereo EEG centre or an epilepsy surgery unit, but my work is actually looking at antibody associated epilepsy, where we find certain patients are affected by antibodies in the CSF or the brain fluid and we think that those antibodies directly are responsible for seizure generation. The way we discovered that was by using the stereo EEG methodology and really analysing the clinical features in those cases. So my preliminary work showed that there was a cluster of really specific symptoms in these patients, the most important of which was they had peri-silvian seizures, which is an area at the side of the brain which generates really unique symptoms that we can identify clinically and investigate them further and potentially prevent them from going for unnecessary surgeries. So this award will help us with our large prospective trial to try and confirm these features in a large group of epilepsy patients and the reason that this is so important is these cases don't respond to the typical anti-seizure medications that we use, but they respond sometimes profoundly to immune-based therapies. So when we use things like steroids and immunoglobulin almost universally, the patients will respond better than when they got anti-epileptic therapies and about 50% of my cohort are actually now seizure-free, which equates to almost a cure for this subtype of epilepsy. So obviously it's interesting and it will change our clinical approach to the diagnosis of epilepsy, but more importantly it affects our management and it really changes the lives of these patients. So thank you.